Targeted Oncology Therapeutics

$4,850.00

A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological and emotional burden of cancer.

Category:

Description

As immunotherapeutics in general – and immuno-oncology in particular – move to the forefront, the major oncology drug developers are beginning to align with specific therapeutic approaches, such as PARP and PD-1/PD-L1. Our analytics analysis of current active oncology trial data reveals these factors and how they are affecting the oncology drug development landscape.